雷贝拉唑钠肠溶片在中国健康受试者中餐后的随机、开放、两制剂、三序列、三周期部分重复交叉设计的生物等效性研究
[Translation] Bioequivalence study of rabeprazole sodium enteric-coated tablets after meals in healthy Chinese subjects in a randomized, open-label, two-drug, three-sequence, three-cycle partial repeat crossover design bioequivalence study
评价中国健康受试者餐后状态下单次口服雷贝拉唑钠肠溶片受试制剂(20 mg,山东裕欣药业有限公司)和参比制剂(波利特®(Pariet®),20 mg,持证商为Eisai Co., Ltd.(エーザイ株式会社))后两种制剂是否具有生物等效性
[Translation] To evaluate the test preparation (20 mg, Shandong Yuxin Pharmaceutical Co., Ltd.) and the reference preparation (Pariet®) after a single oral dose of rabeprazole sodium enteric-coated tablets in healthy subjects in China. 20 mg, the licensee is Eisai Co., Ltd. (エーザイ Co., Ltd.) Are the latter two preparations bioequivalent?
中国健康受试者空腹和餐后单次口服盐酸伐昔洛韦片的单中心、随机、开放、两序列、两周期交叉设计的生物等效性研究
[Translation] Bioequivalence study of a single-center, randomized, open-label, two-sequence, two-period crossover design of a single oral dose of valacyclovir hydrochloride tablets in Chinese healthy subjects
评价中国健康受试者空腹或餐后状态下单次口服盐酸伐昔洛韦片受试制剂(0.5g,山东裕欣药业有限公司)和参比制剂(0.5g,Valtrex®(维德思®),The Wellcome Foundation Limited)后两种制剂是否具有生物等效性、伐昔洛韦及其代谢物阿昔洛韦的药代动力学特征以及安全性。
[Translation] To evaluate the test preparation (0.5g, Shandong Yuxin Pharmaceutical Co., Ltd.) and the reference preparation (0.5g, Valtrex® (Videx®) after a single oral dose of valacyclovir hydrochloride tablets in Chinese healthy subjects on an empty stomach or after meals. ®), The Wellcome Foundation Limited) whether the latter two formulations are bioequivalent, pharmacokinetics of valacyclovir and its metabolite acyclovir, and safety.
中国健康受试者空腹和餐后单次口服利伐沙班片的随机、开放、两序列、四周期完全重复交叉设计的生物等效性试验
[Translation] A randomized, open-label, two-sequence, four-cycle complete repeat crossover design of a bioequivalence trial of a single oral rivaroxaban tablet in Chinese healthy subjects
研究空腹和餐后状态下单次口服利伐沙班片受试制剂(20mg,山东裕欣药业有限公司)与利伐沙班片参比制剂( 20mg,Xarelto®(拜瑞妥®), Bayer AG)后两种制剂是否具有生物等效性、利伐沙班的药代动力学特征和安全性。
[Translation] To study the test preparation of rivaroxaban tablets (20mg, Shandong Yuxin Pharmaceutical Co., Ltd.) and the reference preparation of rivaroxaban tablets (20mg, Xarelto® (Xarelto®) in fasting and postprandial states, Bayer AG) whether the latter two formulations are bioequivalent, the pharmacokinetics and safety of rivaroxaban.
100 Clinical Results associated with Shandong Yuxin Pharmaceutical Co., Ltd.
0 Patents (Medical) associated with Shandong Yuxin Pharmaceutical Co., Ltd.
100 Deals associated with Shandong Yuxin Pharmaceutical Co., Ltd.
100 Translational Medicine associated with Shandong Yuxin Pharmaceutical Co., Ltd.